Roche Launches Automated Digital Pathology Algorithm uPath PD-L1 (SP263) to Enhance Speed and Accuracy of NSCLC Diagnosis

June 28, 2020 /BioValleyBIOON/ -- Roche recently announced the launch of uPath PD-L1 (SP263), an automated digital pathology algorithm certified with CE-IVD marking by the European Union, for image analysis in non-small cell lung cancer (NSCLC). This algorithm enables pathologists to automatically assess scanned slide images in an objective and reproducible manner, with the potential to assistDiagnosis, and ultimately provide targeted treatment plans for patients.

Validated by VENTANA PD-L1 (SP263) assay, the algorithm is available on Roche uPath EnterpriseSoftwareused and integrated in, theSoftwareis a universal digital platform for case management, collaboration, and reporting. The algorithm will help pathologists rapidly determine whether tumors are PD-L1 biomarker-positive, highlighting positively and negatively stained tumor cells with clear visual overlays for easy reference. PD-L1 biomarker-positiveTumorThe patient may be eligible for targeted therapy.

Thomas Schinecker, CEO of Roche Diagnostics, stated: “Improving diagnostic consistency and certainty is essential to providing cancer patients with faster, higher-quality, and more accurateDiagnosiscrucial. Our uPath PD-L1 (SP263) image analysis for non-small cell lung cancer is the first next-generation CE-IVD PD-L1 algorithm directed at the clinical market. It expands our growing VENTANA digital pathology analysis suite, helping physicians provide the most accurate treatment decisions for patients with the most common type of lung cancer.”

The algorithm’s whole-slide automated analysis employs artificial intelligence to provide objective and reproducible assessment of scanned slide images with a single click. The uPath PD-L1 (SP263) Image Analysis (NSCLC) Algorithm for digital pathology is used on the uPath Enterprise Software.

AboutuPath PD-L1 (SP263) Algorithm for NSCLC Image Analysis：

This algorithm is a method to assist pathologists in detecting and semi-quantitatively assessing PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) NSCLC tissues. When used in conjunction with the CE-marked VENTANA PD-L1 (SP263) assay, it is intended as an aid to help determine eligibility for treatment with PD-L1TumorTarget patients for therapeutic products with a T-cell (TC) positivity rate ≥50%. This algorithm is used forIn Vitro Diagnostics, assisting pathologists in displaying, detecting, counting, reviewing, and classifying tissues and cells of clinical interest based on specific morphology, color, intensity, size, pattern, and shape.(Bio Valley Bioon.com)

Original Source:Roche improves speed and accuracy of non-small cell lung cancer diagnosis with launch of automated digital pathology algorithm